A Comparative Study of Mesenchymal Stem Cells from Various Sources in Endometrial Repair: the Significant Advantages of Decidual Mesenchymal Stem Cells.
Yu X., Shi L., Zhang Y., Wang H., Wang H.
Animal Study, published in Stem Cell Rev Rep (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Stem Cell Rev Rep (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40762881
- DOI
- 10.1007/s12015-025-10950-4
Abstract (original English)
Endometrial injury, particularly intrauterine adhesions (Asherman's syndrome), significantly compromises female fertility. Current treatments, including hysteroscopic surgery, intrauterine barriers, and oral estrogen, have limited efficacy, with postoperative pregnancy rates of 22.2-33.3%. Mesenchymal stem cells (MSCs) offer a promising alternative due to their multilineage differentiation and tissue repair capabilities. This study compared the efficacy of MSCs derived from bone marrow, umbilical cord, adipose tissue, and decidua in repairing damaged endometrium. Proliferation of MSCs was assessed using the CCK8 assay. In vitro differentiation into endometrial epithelial cells was evaluated via immunofluorescence and Western blot. In vivo, a rat model of intrauterine adhesion was used to assess endometrial repair following MSC infusions. Bone marrow MSCs had the highest proliferation rate, while adipose-derived MSCs had the lowest. Decidual MSCs exhibited superior differentiation into endometrial epithelial cells and the most effective in vivo repair. Decidual MSCs show superior efficacy in endometrial repair, highlighting their potential for treating intrauterine adhesions. Future studies should focus on clinical validation and mechanistic exploration.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.